Kala Pharmaceuticals(KALA) - 2025 Q2 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 1167 Massachusetts Avenue Arlington, MA 02476 (Address of principal executive offices) (Zip Code) (781) 996-5252 (Registrant's telephone number, including area code) | Securities regi ...